FibroBiologics, Inc.

FibroBiologics, Inc. is a clinical-stage biotechnology company headquartered in Houston, Texas, focused on developing and commercializing fibroblast-based therapies. The company's mission is to create treatments and potential cures for chronic diseases with significant unmet medical needs, leveraging the therapeutic potential of fibroblasts.

FibroBiologics' proprietary fibroblast platform underpins a diverse pipeline of product candidates targeting various chronic conditions. Key therapeutic programs include CYWC628 for diabetic foot ulcers and wound healing, CYMS101 for multiple sclerosis, and CybroCell for degenerative disc disease. The company also has early-stage research in areas such as psoriasis (CYPS317), cancer immunotherapy (CYTER915), thymic involution reversal (TCB190), and diabetes (CYAPO913). FibroBiologics holds an extensive patent portfolio with over 270 issued and pending patents across these clinical pathways.

Led by CEO and Chairperson Pete O'Heeron, FibroBiologics is actively advancing its pipeline and strengthening its market position. In April 2026, the company reported its Q1 2026 financial results, completed manufacturing of its CYWC628 drug product for an upcoming Phase 1/2 clinical trial, and announced positive preclinical results for its burn program and a chondrocyte spheroid therapy for degenerative disc disease. The company also successfully regained compliance with Nasdaq listing requirements and secured additional capital through a direct offering and an At Market Issuance agreement in early May 2026.